A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index =27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. (NCT06383390)
TRIUMPH
This trial is Currently recruiting
Registration number NCT06383390
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Endocrine & Diabetes program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Anthony Russell, Associate Professor Priya Sumithran
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.